Search - tctmd.com

Displaying 81 - 100 of 319

Sort: Relevancy | Date

Presentation

Comparison of Everolimus- and Biolimus-Eluting Coronary Stents with Everolimus-Eluting BVS

Presenter: A.Puricel

February 26, 2015

News Daily News

EVERBIO II Published: BVS Matches Leading DES for Midterm Outcomes

L.A. McKeown

February 26, 2015

News Daily News

XAMI at 3 Years: Rates of Very Late Stent Thrombosis Similarly Low for EES, SES in Acute MI Patients

L.A. McKeown

January 29, 2015

News Daily News

XAMI a los 3 Años: Similares Índices Bajos de Trombosis Muy Tardía del Stent para SLE, SLS y Pacientes que sufren IAM

L.A. McKeown

January 29, 2015

News Daily News

Year in Review: Physicians Highlight the Most Important Interventional News of 2014

Todd Neale

January 12, 2015

News Daily News

ASSURE Registry: Angiographic, Clinical Outcomes of BRS Similar to DES at 1 Year

L.A. McKeown

December 21, 2014

News Daily News

OCTOPUS: Combo of BMS Plus Paclitaxel Balloon Appears Safe But May Be Outdated

December 14, 2014

News Conference News AHA 2014

Biodegradable-Polymer DES Perform Well But Appear No Safer than Their Durable-Polymer Counterparts

November 18, 2014

News Daily News

Immediate, Midterm Outcomes Encouraging for Bioresorbable Scaffolds in STEMI

Todd Neale

November 17, 2014

News Daily News

TWENTE: Second-Generation DES Show Good Long-term Outcomes in Bifurcation Lesions

L.A. McKeown

November 02, 2014

Presentation TCT 2014

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

Presenter: Mitchell W. Krucoff, Giulio G. Stefanini, Stephane Cook

September 16, 2014

Presentation TCT 2014

Comparison of Novel Zotarolimus-Eluting Cobalt-Chromium Stents and Everolimus-Eluting Platinum-Chromium Stents in Patients of the Randomized DUTCH PEERS Trial Presenting with___

Presenter: Marije L?wik

September 16, 2014

Presentation TCT 2014

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

Presenter: Krishnankutty Sudhir

September 16, 2014

Presentation TCT 2014

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

Presenter: Georgios Vlachojannis

September 16, 2014

News Industry News

New All-Comers Study Compares Efficacy of Bioresorbable Vascular Scaffold to Best-in-Class Drug Eluting Stents

September 16, 2014

News Conference News TCT 2014

Keynote Address Focuses on Newer DES, Problematic Subgroups

September 15, 2014

News Conference News TCT 2014

EES Decrease Restenosis, TVR vs. BMS in Non-STEMI

September 15, 2014

Presentation TCT 2014

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

Presenter: Donald Cutlip, Manel Sabate, Elvin Kedhi, Lisette Okkels Jensen

September 14, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

News Conference News TCT 2014

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

September 14, 2014

Advertisement

Comparison of Everolimus- and Biolimus-Eluting Coronary Stents with Everolimus-Eluting BVS

EVERBIO II Published: BVS Matches Leading DES for Midterm Outcomes

XAMI at 3 Years: Rates of Very Late Stent Thrombosis Similarly Low for EES, SES in Acute MI Patients

XAMI a los 3 Años: Similares Índices Bajos de Trombosis Muy Tardía del Stent para SLE, SLS y Pacientes que sufren IAM

Year in Review: Physicians Highlight the Most Important Interventional News of 2014

ASSURE Registry: Angiographic, Clinical Outcomes of BRS Similar to DES at 1 Year

OCTOPUS: Combo of BMS Plus Paclitaxel Balloon Appears Safe But May Be Outdated

Biodegradable-Polymer DES Perform Well But Appear No Safer than Their Durable-Polymer Counterparts

Immediate, Midterm Outcomes Encouraging for Bioresorbable Scaffolds in STEMI

TWENTE: Second-Generation DES Show Good Long-term Outcomes in Bifurcation Lesions

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

Comparison of Novel Zotarolimus-Eluting Cobalt-Chromium Stents and Everolimus-Eluting Platinum-Chromium Stents in Patients of the Randomized DUTCH PEERS Trial Presenting with___

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

New All-Comers Study Compares Efficacy of Bioresorbable Vascular Scaffold to Best-in-Class Drug Eluting Stents

Keynote Address Focuses on Newer DES, Problematic Subgroups

EES Decrease Restenosis, TVR vs. BMS in Non-STEMI

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content